Annals of Oncology 13:831-839, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Measuring cancer prevalence in Europe: the EUROPREVAL Project
1Istituto Superiore di Sanità, Rome, Italy; 2Isère Cancer Registry, Grenoble, France; 3Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; 4FRANCIM, Toulose, France
Received 4 May 2001; revised 12 December 2001; accepted 13 December 2001.
Cancer prevalence is the proportion of individuals in a population who at some stage during their lifetime have been diagnosed with cancer, irrespective of the date of diagnosis. Cancer prevalence statistics have generally been provided by a limited number of well established cancer registries that have been in existence for several decades. The advent of systematic follow-up of life status of incident cases and the availability of new statistical methodologies, now makes it possible for registries established during the 1970s or 1980s to provide prevalence data. The main problems encountered in the estimation of prevalence are the inclusion of: (i) cases lost to follow-up; (ii) cases known only from their death certificate; (iii) cases diagnosed before the start of registration; and (iv) the treatment of multiple tumours and migrations. The main aim of this paper was to review these problems and discuss, through the experience gained with EUROPREVAL, how they can be overcome. A method is presented for the calculation of prevalence of all cancers combined in the populations covered by the 45 cancer registries participating in EUROPREVAL. Prevalence of cancer is estimated to be 2% on average, with the highest values (3%) in Sweden and the lowest in Eastern Europe, with a minimum of 
1% in Poland.
Key words: epidemiology, Europe, methods, prevalence, tumours
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. Kerr and D. Khayat The Entente Cordiale--natural and necessary Ann. Onc., November 1, 2004; 15(11): 1581 - 1581. [Full Text] [PDF]
|
|
|
|
 |
|
 C Gras, J P Daures, and B Tretarre Age and stage specific prevalence estimate of cancer from population based Cancer Registry using inhomogeneous Poisson process Statistical Methods in Medical Research, August 1, 2004; 13(4): 273 - 289. [Abstract] [PDF]
|
|
|
|
|
|
G. Gatta, R. Capocaccia, F. Berrino, M. R. Ruzza, P. Contiero, and the EUROPREVAL Working Group Colon cancer prevalence and estimation of differing care needs of colon cancer patients Ann. Onc., July 1, 2004; 15(7): 1136 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Moller, H. Anderson, T. Aareleid, T. Hakulinen, H. Storm, L. Tryggvadottir, I. Corazziari, and E. Mugno Cancer prevalence in Northern Europe: the EUROPREVAL study Ann. Onc., June 1, 2003; 14(6): 946 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Forman, D. Stockton, H. Moller, M. Quinn, P. Babb, R. De Angelis, and A. Micheli Cancer prevalence in the UK: results from the EUROPREVAL study Ann. Onc., April 1, 2003; 14(4): 648 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Lutz, S. Francisci, E. Mugno, M. Usel, V. Pompe-Kirn, J.-W. Coebergh, and M. Bieslka-Lasota Cancer prevalence in Central Europe: the EUROPREVAL Study Ann. Onc., February 1, 2003; 14(2): 313 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Verdecchia, A. Micheli, M. Colonna, V. Moreno, M. I. Izarzugaza, and E. Paci A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain Ann. Onc., July 1, 2002; 13(7): 1128 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Giles How important are estimates of cancer prevalence? Ann. Onc., June 1, 2002; 13(6): 815 - 816. [Full Text] [PDF]
|
|
|
|
|
|
A. Micheli, E. Mugno, V. Krogh, M. J. Quinn, M. Coleman, T. Hakulinen, G. Gatta, F. Berrino, R. Capocaccia, and the EUROPREVAL Working Group Cancer prevalence in European registry areas Ann. Onc., June 1, 2002; 13(6): 840 - 865. [Abstract] [Full Text] [PDF]
|
|